Monjri Shah, MD
Gynecologic Oncology · Birmingham, ALNPI 1275791592
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 102 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $619, 5.8 times the $106 reported in 2019.
Across 102 payments — averaging $23.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$338
- Intuitive Surgical$269
- Novartis$266
- Octapharma USA, Inc.$218
- Daiichi Sankyo Inc.$176
- Caris MPI, Inc.$136
- plus $978 from 27 others
What the payments were for
- Food & beverage$2,378100%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 13 | $338 |
| Intuitive Surgical | 5 | $269 |
| Novartis | 14 | $266 |
| Octapharma USA, Inc. | 11 | $218 |
| Daiichi Sankyo Inc. | 8 | $176 |
| Caris MPI, Inc. | 1 | $136 |
| Karyopharm Therapeutics Inc. | 2 | $110 |
| Eisai Inc. | 4 | $90 |
| AbbVie | 3 | $81 |
| Astellas Pharma US Inc | 3 | $65 |
| Conmed Corporation | 4 | $56 |
| Pharmacosmos Therapeutics Inc. | 2 | $56 |
| GSK | 3 | $54 |
| Clovis Oncology, Inc. | 4 | $45 |
| AstraZeneca(2 entities) | 3 | $45 |
| Seagen Inc. | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Taiho Oncology, Inc. | 2 | $29 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $29 |
| Pharmaessentia USA Corporation | 1 | $26 |
| Recordati_rare_diseases_inc. | 1 | $22 |
| Tesaro, Inc. | 1 | $22 |
| Telix Pharmaceuticals | 1 | $21 |
| Johnson & Johnson | 1 | $18 |
| Acrotech Biopharma Inc. | 1 | $18 |
| Novocure Inc. | 1 | $18 |
| AVEO Pharmaceuticals, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Fennec Pharmaceuticals, Inc. | 1 | $16 |
| Beone Medicines USA, Inc. | 1 | $16 |
| Myriad Genetic Laboratories, Inc. | 1 | $16 |
| Bristol Myers Squibb | 1 | $15 |
| Integra Lifesciences Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,380 in reported general payments places this provider in the 55th percentile of 27 gynecologic oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $6,153 |
| Estradiol | 26 | $2,196 |
| Clobetasol Propionate | 20 | $1,180 |
| Letrozole | 20 | $493 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 89 | $457 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 39 | $222 |
| Ondansetron OdtOndansetron | 12 | $179 |
| Duloxetine Hcl | 11 | $169 |
| Nystatin | 12 | $156 |
| Fluconazole | 15 | $150 |
| Ondansetron Hcl | 14 | $52 |
| Methocarbamol | 11 | $42 |
| Tramadol Hcl | 12 | $34 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Birmingham
- Charles LeathBirmingham$148K
- Rebecca ArendBirmingham$70K
- Warner HuhBirmingham$59K
- David DooBirmingham$9K
- Michael ToboniBirmingham$8K
- Margaret LiangBirmingham$3K
- Wesley BurkettBirmingham$3K
- Kaitlyn DinkinsBirmingham$2K
- Christopher MayerBirmingham$1K
- Teresa BoitanoBirmingham$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.